GSK Jan 2025 23.000 put

OPR - OPR Delayed price. Currency in USD
0.6000
0.0000 (0.00%)
As of 09:57AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close0.6000
Open0.6000
Bid0.6000
Ask0.8500
Strike23.00
Expiry date2025-01-17
Day's range0.6000 - 0.6000
Contract rangeN/A
Volume1
Open interest212
  • Business Wire

    BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition

    MONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl

  • Simply Wall St.

    Interested In GSK's (LON:GSK) Upcoming UK£0.14 Dividend? You Have Four Days Left

    GSK plc ( LON:GSK ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one business day before...

  • Yahoo Finance UK

    Trending tickers: GSK | THG | Beazley | Disney

    The latest investor updates on stocks that are trending on Friday.

  • Yahoo Finance UK

    Wall Street loses ground as FTSE 100 closes higher on UK economy growth

    FTSE 100 closes the week higher as the UK economy returned to growth.

  • GlobeNewswire

    SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

    STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that data from two collaborator-sponsored clinical studies evaluating nirogacestat, an investigational oral gamma secretase inhibitor, in combination with B-cell maturation agent (BCMA) therapies in patients with relapsed or refractory multiple my

  • Motley Fool

    The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer

    Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.

  • GlobeNewswire

    SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

    SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment from GSK of $90 million upon deal close with future performance-based milestone payments of up to $503 million and tiered royalties.SCYNEXIS ended Q1 with cash, cash equivalents and short-term investments of $54.8 million, and upon receipt of the upfront payment from GSK will have a projecte

  • Simply Wall St.

    GSK plc (LON:GSK) is favoured by institutional owners who hold 82% of the company

    Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading actions...

  • Yahoo Finance Video

    GSK’s vaccine against RSV wins FDA approval

    Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss the FDA’s approval of GlaxoSmithKline’s (GSK) vaccine against RSV.

  • Business Wire

    US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

    PHILADELPHIA, May 03, 2023--US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults

  • The Telegraph

    Investors may be sceptical, but this unloved stock has much to offer – and a lowly valuation

    Here is an unloved stock that offers a new group structure, the potential resolution of legal woes, the presence of an activist investor, a clear strategy, a building pipeline of vaccines and medicines – and all with a lowly valuation.

  • Yahoo Finance

    Pfizer to shift focus to new products amid decline in COVID sales

    Pfizer reported strong earnings for the first quarter of the year, despite a decrease in COVID product demand. However, investors are wary of the company's anticipated product launches this year.

  • Yahoo Finance Video

    Why the human genome could be health care’s holy grail

    23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.” The 23andMe (ME) CEO also says they are looking into building new partnerships with pharmaceutical giants once the company’s partnership with GlaxoSmithKline (GSK) ends in July. Interview Highlights: 1:29 How genetics can tell us more about human diversity 2:20 Why 23andMe CEO is ‘disappointed’ about genome adoption 5:00 Wojcicki on 23andMe partnership with pharma giant GSK 7:15 Genetics needs to be part of medical school training 8:26 What’s next for 23andMe

  • Yahoo Finance

    23andMe CEO: We see more opportunities in DNA partnerships

    23 & Me CEO Anne Wojicki reveals the next key opportunity for her company.

  • Motley Fool

    Was This Acquisition a Savvy Play by This Big Pharma Stock?

    Earlier this month, U.K.-based drugmaker GSK (NYSE: GSK) reached a deal to buy Canadian biotech company Bellus Health (NASDAQ: BLU) for $2 billion in cash. Should GSK's deal for Bellus Health be approved by regulatory authorities and a two-thirds majority of the latter's shareholders, the former will pick up a promising drug candidate, camlipixant, that aims to treat refractory chronic cough (RCC). Surprisingly, there are no approved therapies for RCC in the United States or the European Union.

  • Zacks

    GSK (GSK) Tops Q1 Earnings Estimates

    Glaxo (GSK) delivered earnings and revenue surprises of 5.88% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • Yahoo Finance UK

    Trending tickers: Microsoft | Alphabet | First Republic | Meta | GSK

    A look at the stocks making headlines on Wednesday.

  • Evening Standard

    End of the road for Covid turnover, GSK says

    GSK has signalled the end of the road for its Covid drug sales boom as the pharma giant eyes fresh sources of revenue to plug the hole left by the subsidence of the pandemic. The London-based business posted a 15% drop in operating profits to £2.1 billion and an 8% fall in turnover in the first three months of 2023 to just under £7 billion. The firm said: “Based on known binding agreements with governments, GSK does not anticipate further significant COVID-19 pandemic-related sales or operating profit in 2023.”

  • Motley Fool

    Why Shares of Bellus Health Skyrocketed This Week

    Shares of Bellus Health (NASDAQ: BLU) jumped 105.1% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The company, which received a $2 billion buyout offer from GSK (formerly known as GlaxoSmithKline) (NYSE: GSK), closed at $7.06 last week and reached a new 52-week high at $14.50 on Tuesday. The attraction for GSK is camlipixant, Bellus' late-stage pipeline candidate to treat adults with refractory chronic cough (RCC).

  • Business Wire

    GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

    LONDON, April 18, 2023--GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 billion). The acquisition provides GSK access to camlipixant

  • Motley Fool

    Why BELLUS Health Stock Is Rocketing Higher Today

    What happened Shares of BELLUS Health (NASDAQ: BLU) were up by a whopping 98.9% as of 10:19 a.m. ET Tuesday morning. The big gain came in response to a $2 billion buyout agreement with British pharma giant GSK (NYSE: GSK).

  • Evening Standard

    GSK unveils £1.6 billion deal to buy Canadian medicine maker Bellus Health and its blockbuster cough drug

    The deal is the biggest since the old GlaxoSmithKline split in two by separating its consumer products arm

  • Motley Fool

    Is Arrowhead Pharmaceuticals a Buy Now?

    The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.

  • Motley Fool

    Can Pfizer Beat GSK and Moderna in This $10 Billion Market?

    Pfizer (NYSE: PFE) and GSK (NYSE: GSK) have competed against each other for years. Moderna (NASDAQ: MRNA) is a more recent rival, with its COVID-19 vaccine, SpikeVax, going head to head with Pfizer's Comirnaty. Can Pfizer beat GSK and Moderna in this $10 billion market?

  • Motley Fool

    Why Shares of Adaptimmune Therapeutics Jumped Tuesday

    Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the rights to Adaptimmune's PRAME and NY-ESO cell therapy programs. Adaptimmune focuses on therapies to treat cancer in solid tumors through its SPEAR (for Specific Peptide Enhanced Affinity Receptor) T-cell platform. The company has four SPEAR T-cells in trials: MAGE-A10, MAGE-A4, AFP, and NY-ESO.